Table 1 Study sample characterization variables
Variables (n = 49 patients, 53 sessions) | Measurements |
|---|---|
Men, n (%) | 37 (69.8) |
Age (years), median (IQR) | 53.8 (40-68) |
Weight (kg), median (IQR) | 79.94 (69-87) |
ICU stay days, median (IQR) | 30.73 (15-40) |
Therapy indication | |
Refractory hyperkalemia, n (%) | 10 (18.9) |
Refractory metabolic acidosis, n (%) | 14 (26.4) |
Uremic syndrome, n (%) | 5 (9.4) |
Refractory hypervolemia, n (%) | 14 (26.4) |
Dysnatremia, n (%) | 6 (11.3) |
Intoxication, n (%) | 5 (9.4) |
Anuria, n (%) | 38 (71.6) |
Blood flow (mL/min), median (IQR) | 150 (120-150) |
Sodium citrate flow 4% (mL/h), median (min-max) | 260 (130-270) |
Dose of sodium citrate (mmol/h), median (min-max) | 30 (15-31) |
Calcium gluconate replacement flow (mL/h), median (min-max) | 22.0 (8-25) |
Dose of calcium replaced (mmol/h), median (min-max) | 1.84 (1.84-2.30) |
Comorbidities | |
CKD, n (%) | 28 (52.8) |
Coronary artery disease, n (%) | 14 (26.4) |
Diabetes Mellitus, n (%) | 27 (50.9) |
Arterial Hypertension, n (%) | 32 (61.5) |
Obesity, n (%) | 17 (32.1) |
COVID-19, n (%) | 29 (54.7) |
General in-hospital mortality, n (%) | 45 (84.9) |
In-hospital mortality from COVID-19, n (%) | 27 (93.1) |
CKD, n (%) | 14 (26.4) |
Stage GFR 2, n (%) | 1 (1.9) |
Stage GFR 3, n (%) | 2 (3.8) |
Stage GFR 4, n (%) | 5 (9.4) |
Stage GFR 5, n (%) | 6 (11.3) |
AKI on arrival from the ICU, n (%) | 45 (84.9) |
KDIGO I, n (%) | 4 (9.3) |
KDIGO II, n (%) | 10 (23.3) |
KDIGO III, n (%) | 29 (67.4) |
Administration of vasoactive drug, n (%) | 34 (64.2) |
Mechanical ventilation, n (%) | 43 (82.7) |